NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care - BD Awarded $100 Million Contract for Enterprise-Wide Automated Medication Dispensing Across 115 Military Health Facilities - BD.com
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care

 

NewswireTODAY - /newswire/ - Franklin Lakes, NJ, United States, 2017/03/01 - BD Awarded $100 Million Contract for Enterprise-Wide Automated Medication Dispensing Across 115 Military Health Facilities - BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that it was awarded a contract worth up to $100 million with the Defense Health Agency (DHA) under the U.S. Department of Defense (DoD) for its Pyxis™ ES System. Under the purchase agreement, BD will provide its enterprise-wide medication dispensing technology platform across the DHA’s 115 military inpatient health facilities and military inpatient pharmacies.

“Through this collaboration with the DoD, we have the opportunity to help modernize the DHA’s medication management and dispensing systems across all of the organization’s facilities in the United States, Asia and Europe,” said Ranjeet Banerjee, worldwide president of Medication Management for BD. “We are honored to expand our longstanding partnership with the organization, to both upgrade existing legacy Pyxis sites to an enterprise-wide solution, as well as expand our footprint across all DHA facilities.”

Key solution areas include:

• The Pyxis ES System’s Automated Dispensing Cabinet (ADC) meets the highest quality standards for implementation at military treatment facilities across the Military Health System;
• Proven pharmacy inpatient automation solution with flexibility to handle multiple architecture configurations supporting decentralized deployments;
• Flexibility to consolidate configurations and scale the system via a centralized enterprise-wide platform;
• Secure storage of medication and pharmaceutical items;
• Provides automated system administration with tracking and management of medications;
• Provides advanced data analytics and reporting capabilities;
• Supports industry standard interface and integration capabilities and compatibilities.

Under the terms of the agreement, BD will provide its industry leading Pyxis ES System consisting of Pyxis™ Enterprise Server, Pyxis MedStation™ ES system, Pyxis™ Smart CUBIE™ technology, and integrated analytics tools the Knowledge Portal for Pyxis™ medication technologies. This contract award is contemplated in the company’s fiscal year 2017 guidance.

The Pyxis ES System is a scalable, web-based platform specifically designed to improve medication management across the continuum of care. The Pyxis ES platform promotes a patient-centric health care model, leveraging HIT system and Active Directory integration to enable a single health system formulary, simplified identity management and workflow enhancements. The platform enables pharmacists to manage medications remotely and eliminate redundant tasks. Nurses can readily access secured medications using safe and simple workflows that are centered on the patient.

For more information about the Pyxis Enterprise Solution, please visit carefusion.com/pyxis.

About BD
BD (bd.com) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

BD Contact: Monique N. Dolecki - BD Investor Relations
P: 201 847 5378 - E: monique_dolecki[.]bd.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BD | Pyxis™ ES System
Contact: Matthew Coppola - BD.com 
201-847-7370 matthew_r_coppola[.]bd.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Becton, Dickinson and Company / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit BizJobs.com

Visit  RightITnow, Inc.





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)